Apellis Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: APLS · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1492422
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: APLS
TL;DR
APLS filed an 8-K for a shareholder vote. Details TBD.
AI Summary
Apellis Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of security holders as of June 3, 2025. The filing does not detail the specific matters voted upon but indicates a formal submission to the SEC regarding corporate governance or shareholder decisions.
Why It Matters
This filing signals that Apellis Pharmaceuticals has held or is holding a shareholder vote, which is a key event in corporate governance and can impact company direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- June 4, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Apellis Pharmaceuticals' security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not enumerate the specific proposals or resolutions voted upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 3, 2025.
What is the filing date of this 8-K report?
The 8-K report was filed on June 4, 2025.
What is the principal executive office address for Apellis Pharmaceuticals, Inc.?
The principal executive offices are located at 100 Fifth Avenue, Waltham, MA 02451.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Apellis Pharmaceuticals, Inc. (APLS).